Astra’s Experimental Stomach Cancer Drug Doubled Survival Time
AstraZeneca’s experimental drug significantly extended survival for stomach cancer patients in a late-stage trial, offering new hope for those with limited treatment options. The results suggest a potential breakthrough, with the drug poised to become a major new therapy.
Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review our Terms of Service and Cookie Policy.
Bloomberg
